Medtronic (MDT) offers a wide portfolio of TrailBlazer support catheters, which help physicians offer specialized treatment of complex lesions of the knee. In the United States, around 8.5 million people suffer from peripheral artery diseases, according to the Centers for Disease Control and Prevention. The trailblazer support catheters are procedural support products marketed under the peripheral therapies business unit of Medtronic. Medtronic’s peripheral business is part of the company’s Aortic and Peripheral Vascular division which is part of the Cardiac and Vascular Group (or CVG). To learn more about Medtronic’s Cardiac and Vascular Group, read Evaluating Medtronic’s Cardiac and Vascular Devices Segment.
The company received clearance from the U.S. Food, Drug and Administration (or FDA) for its TrailBlazer Angled Peripheral Support Catheter on September 23.
Features and benefits of Minimed 670G
As per the company’s press release, “The new TrailBlazer angled support catheter is designed to support a guide wire during access to the peripheral arteries, and to enable delivery of solutions and diagnostic agents. The catheter features a braided stainless steel shaft for robust pushability and a 25 and 30 degree angled tapered tip to access and cross complex lesions. To enhance physician visibility, each of the .014″, .018″ and .035″ guidewire compatible devices is designed with three radiopaque marker bands and a radiopaque shaft. Additionally, both the .014″ and .018″ TrailBlazer angled support catheter can fit coaxially through the .035″ support catheter for increased reach and pushability.”
Boston Scientific (BSX), St. Jude Medical (STJ), and Edwards Lifesciences (EW) are Medtronic’s major competitors in the cardiac and vascular segment. The iShares S&P 500 Growth ETF (IVW) invests ~0.69% of its total holdings in Medtronic.